[
  {
    "abstract_id": "OW-2026-T-OR-12",
    "title": "Retatrutide 12mg in adults with obesity without diabetes — Phase 3 TRIUMPH-mock results",
    "authors": "Mock Z, Mock AA",
    "abstract_text": "Synthetic Phase 3 weight-loss results for retatrutide (LY3437943) at 12mg weekly in obesity without diabetes. Placebo-adjusted weight loss -22.1% at 88 weeks. GI AE 38.5%. All data synthetic.",
    "phase": "Phase 3",
    "weight_loss_pct": 22.1,
    "gi_ae_pct": 38.5
  },
  {
    "abstract_id": "OW-2026-T-OR-22",
    "title": "Bimagrumab + tirzepatide combination preserves lean mass — Phase 2 (mock)",
    "authors": "Mock AB, Mock AC",
    "abstract_text": "tirzepatide+bimagrumab combination produced mock -18.7% placebo-adjusted body weight at 48 weeks while preserving lean mass (synthetic DEXA endpoints) in a Phase 2 cohort. GI AE 27.0%. Mock data.",
    "phase": "Phase 2",
    "weight_loss_pct": 18.7,
    "gi_ae_pct": 27.0
  },
  {
    "abstract_id": "OW-2026-T-OR-31",
    "title": "Setmelanotide in syndromic obesity — Phase 4 long-term safety (mock)",
    "authors": "Mock AD",
    "abstract_text": "Setmelanotide MC4R agonist long-term safety in a synthetic Phase 4 syndromic obesity registry. Mean weight loss -10.1%, GI AE 11.5%. All data mock.",
    "phase": "Phase 4",
    "weight_loss_pct": 10.1,
    "gi_ae_pct": 11.5
  },
  {
    "abstract_id": "OW-2026-T-PO-141",
    "title": "ARD-101 bitter taste receptor agonist in hypothalamic obesity — Phase 2 (synthetic)",
    "authors": "Mock AE",
    "abstract_text": "ARD-101 (TAS2R agonist) achieved mock -6.4% placebo-adjusted weight loss in synthetic Phase 2 hypothalamic obesity cohort at 24 weeks. GI AE 8.9%. Synthetic mock data only.",
    "phase": "Phase 2",
    "weight_loss_pct": 6.4,
    "gi_ae_pct": 8.9
  },
  {
    "abstract_id": "OW-2026-T-PO-152",
    "title": "GSBR-1290 oral small-molecule GLP-1 — Phase 2 in obesity (mock)",
    "authors": "Mock AF, Mock AG",
    "abstract_text": "GSBR-1290 small-molecule oral GLP-1 RA produced -6.9% placebo-adjusted weight loss at 12 weeks in synthetic Phase 2 obesity cohort. GI AE 19.3%. Mock data.",
    "phase": "Phase 2",
    "weight_loss_pct": 6.9,
    "gi_ae_pct": 19.3
  },
  {
    "abstract_id": "OW-2026-T-PO-161",
    "title": "Mibavademab leptin receptor agonist in lipodystrophy and obesity — Phase 2 (mock)",
    "authors": "Mock AH",
    "abstract_text": "Mibavademab (REGN4461) in lipodystrophy-obesity synthetic Phase 2 cohort: -5.4% placebo-adjusted weight loss at 26 weeks, GI AE 7.2%. Mock data only.",
    "phase": "Phase 2",
    "weight_loss_pct": 5.4,
    "gi_ae_pct": 7.2
  }
]